sales of recombinant drugs

sales of recombinant drugs

Product Protein Effects/ therapeutic use Marketed by Worldwide sales 2005
in US$m
Worldwide sales 2004
in US$m
Worldwide sales 2003
in US$m
Worldwide sales 2002
in US$m
Worldwide sales 2001
in US$m
Worldwide sales 2000
in US$m
Worldwide sales 1999
in US$m
Worldwide sales 1998
in US$m
Worldwide sales 1997
in US$m
Epogen Erythropoeitin* stimulation of the production of erythrocytes Amgen 2455 2601 2400 2300 2200 1960 1760 1380 1161
Procrit/ Eprex Erythropoeitin alfa * stimulation of the production of erythrocytes J&J/ Ortho Biotech 3324 3589 3984 4283 3430 2709 1505 1460 1000
NeoRecormon/ Epogin Erythropoeitin beta * stimulation of the production of erythrocytes Genentech/ Roche/ Chugai 1710 1842 1527 1192 443
Aranesp Darbepoeitin alfa * stimulation of the production of erythrocytes Amgen 3273 2473 1500 400 42
Peg-Intron
(Intron-A)
PEGylated alpha-interferon + ribavirin anti Hepatitis C Schering-Plough 1369 1851 1851 2700 1447 1361 650 598
Pegasys PEGylated interferon alpha-2a + copegus (ribavirin) anti Hepatitis C Roche 1374 1382 762
Avonex Interferon beta-1a multiple sclerosis Biogen Idec 1543 1417 1168 1034 972 761 621 394.9 240
Rebif Interferon-beta-1a multiple sclerosis Serono 1270 1091 819 548,8 379.6 254 143 44 19
Betaseron/
Betaferon
Interferon beta-1b multiple sclerosis Schering AG 1026 1057 929 830 592 546 395 321 297
Neupogen G-CSF stimulation of the production of granulocytes Amgen 1216 1200 1300 1400 1300 1220 1260 1120 1056
Neulasta G-CSF PEG conjugate stimulation of the production of granulocytes Amgen 2288 1700 1300
Leukine GM-CSF stimulation of leukocytes Schering AG 80 77 n.a. 108.4 88.3 69.1 63.8 53
Proleukin Interleukin cancer Chiron 129 115 114 93 113 112 93 71
Humulin Insulin diabetes Eli Lilly 1005 998 1060 1004 1060.6 1114.5 1087.5 959.2 936
Humalog Insulin diabetes Eli Lilly 1198 1102 1021 1004 627.8 350.2
Rituxan
(in EU: Mabthera)
rituximab, humanised MAb leukemia and lymphomes Genentech/ Roche 3154 2989 2243 1163 818.7 444.1 279.4 162.6
Herceptin trastuzumab, humanised anti-HER-2 MAb breast cancer Genentech/ Roche 1629 1270 952 385 346.6 275.9 188.4 30.5
Campath alemtuzumab, humanised MAb against CD52 B-cell chronic lymphoma Genzyme 77 72
Mylotarg gemtuzumab ozogamicin, humanised anti-CD33 MAb relapsed acute myeloid leukemia Wyeth 20 20
Enbrel etanercept (fusion protein of antibody-Fc and p75-TNF receptor protein) rheumatoid
arthritis
Amgen 3657 2580 1300 802 761.9 652.4 366.9
Remicade Infliximab, chimaeric MAb rheumatoid
arthritis, morbus Crohn
J&J 3477 2891 1729 1297 721 116
Humira Adalimumab rheumatoid
arthritis
Abbott 1400 852 280
Humatrope human growth hormone (HGH) Somatotropin dwarfism Eli Lilly 430 371 329 312.7 301 300 268 260
Protropin/Nutropin human growth hormone (HGH) Somatotropin dwarfism Genentech 396 322 297 250 226.6 221.2 214 224
Serostim human growth hormone (HGH) dwarfism Serono 86.8 88.8 95.1 125.3 137.1 137.4 88.2 38.8
Saizen human growth hormone (HGH) dwarfism Serono 182.1 151.5 124 107.3 90.0
Cerezyme/
Ceredase
Glucocerebrosidase Gaucher’s disease Genzyme 932 839 734 619 570 537 479 411 333
Synagis humanised mAb respiratory syncytia virus prevention Abbott/ Medimmune 1063 942 849 668 516 427 293 110
Gonal F Follitropin alpha stimulation of ovulation Serono 572.7 526.1 450,4 410.5 365.9 348.7 243.8 116
Activase tissue plasminogen activator coronary infarct Genentech n.a. 185 180 197 206 236 213
ReoPro GBIIb/IIIa-antibody inhibition of thrombosis Eli Lilly/Centocor 363 364 384 431.4 418.1 447.3 365.4 254
Kogenate Factor VIII hemophilia Bayer <481 497 424 427 327 335 262
Engerix-B envelope protein of the hepatitis B virus vaccine SmithKline Beecham n.a. n.a. 483 641 540 574 584
Pulmozyme human DNAse mucoviscidosis Genentech 299 167 138 123 121.8 111.4 93.8 92
Aldurazyme rec. human alpha-L-iduronidase enzyme replacement theapy mucopolysaccharidosis Genzyme 43 12
Fabrazyme rec. human alpha-glactosidase A enzyme replacement therapy Genzyme 305 209 81
Amevive alefacept severe plaque psoriasis Biogen Idec 43 40
Xolair omalizumab, humanised anti-IgE MAb persistent allergic asthma Genentech, Novartis 188 25
Raptiva efalizumab, humanised anti-CD11a MAb severe plaque psoriasis Genentech, Xoma 57 1
Erbitux cetuximab advanced colorectal cancer ImClone, Merck KGaA 365 (partial year)
Mylotarg gemtuzumab ozogamicin bone marrow cancer (CD33 positive acute myeloid leukemia) Wyeth Ayerst 20 20
Zevalin Ibritumomab Tiuxetan relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma IDEC Pharmaceuticals 23 20
Avastin bevacizumab advanced colorectal cancer Genentech 1264 555 (partial year)

* Information on EPO from BIO-GAL http://www.bio-gal.com/Epo.htm:
EPO was cloned and consequently produced in recombinant genetic engineering by Amgen in 1985. Following extensive clinical trials, it was approved for end-stage kidney disease-related anemia. Later, its approval was broadened to other types of anemia, including cancer-related anemia. The original patent application for Epo was filed by Amgen and subsequently transferred to J&J, which currently sells Epoetin-alfa as Procrit in the U.S. and Eprex in Europe, distributed by Janssen Cilag. Amgen sells EPO under the name Epogen mainly for the U.S. dialysis market. Epoetin-beta is produced and marketed by Hoffman La Roche, under the name Recormon (Chugai markets the Epogin brand in Japan). Epoetin Omega is produced by Elanex and marketed under the Epomax and Hemax names. Most products are licensed and positioned to treat mainly kidney-related and cancer-related anemia. Amgen’s patents expire in 2004 (mainly in Europe). Numerous players are striving to dominate this market, including, among others, Amgen, J&J, Roche, Chugai, Genetics Institute, Kirin and Elanex.

Schreibe einen Kommentar

Deine E-Mail-Adresse wird nicht veröffentlicht. Erforderliche Felder sind mit * markiert.